Volpara to present at RSNA 2014 next generation of VolparaAnalytics.
Volpara will showcase at RSNA 2014 VolparaAnalytics version 1.2.
Volpara Analytics is a centralized dashboard that presents key mammography metrics and automatically collates data from digital mammography and tomosynthesis units to enable cross-comparison of patient populations, mammography systems, and operator performance, Volpara said.
The new version of VolparaAnalytics will feature an enhanced user interface and reporting tools, and deliver expanded breast imaging metrics to users including additional quality metrics, new temporal analysis tools, additional tools to analyze patient positioning and patient dose, and time between study acquisition, Volpara said.
VolparaAnalytics runs on top of VolparaDensity, a software tool that helps radiologists objectively assess density from both digital mammography and tomosynthesis images and determine which women would benefit from additional screening.
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.